Literature DB >> 675246

Cryoprecipitate reversal of opsonic alpha2-surface binding glycoprotein deficiency in septic surgical and trauma patients.

T M Saba, F A Blumenstock, W A Scovill, H Bernard.   

Abstract

Human opsonic alpha2-surface binding glyoprotein (alphs2SB-glycoprotein), a molecule having immunologic identity with an amino acid composition similar to cold-insoluble globulin, is concentrated in a cryoprecipitate of plasma. Septic surgical and trauma patients manifesting opsonic alpha2SB-glycoprotein deficiency and associated reticuloendothelial system dysfunction were treated by intravenous infusion of cryoprecipitate. This therapy restored circulating bioreactive and immunoreactive opsonin and improved their septicemia, pulmonary insufficiency, and duration of recovery. Cryoprecipitate infusion may offer a new approach to the treatment of septic injured patients in preventing multiple organ failure; measurement of immuno-reactive serum opsonic alpha2SB-glycoprotein may provide a noninvasive index of reticuloendothelial system function and patient status during servere sepsis that follows trauma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 675246     DOI: 10.1126/science.675246

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  38 in total

1.  Plasma fibronectin concentrations in blood products.

Authors:  J Perttilä; M Salo; O Peltola
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  A study on content and distribution of plasma and tissue fibronectin in rats using ELISA and immunofluorescence.

Authors:  H M Jin
Journal:  J Tongji Med Univ       Date:  1990

3.  Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides.

Authors:  C Signäs; G Raucci; K Jönsson; P E Lindgren; G M Anantharamaiah; M Höök; M Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Plasma fibronectin concentrations in healthy and septic infants.

Authors:  M Domula; K Bykowska; Z Wegrzynowicz; S Lopaciuk; G Weissbach; M Kopéc
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

5.  Fibronectin and Kupffer cell function in fulminant hepatic failure.

Authors:  M Imawari; R D Hughes; C D Gove; R Williams
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

6.  Fibronectin as an opsonic regulator of monocyte phagocytosis.

Authors:  A W Simpson; B J Boughton
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

Review 7.  Fibronectin and the critically ill patient: current status.

Authors:  T M Saba; J L Kiener; J M Holman
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

8.  Binding of fibronectin to the surface of group A, C, and G streptococci isolated from human infections.

Authors:  L M Switalski; A Ljungh; C Rydén; K Rubin; M Höök; T Wadström
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

9.  Opsonic glycoprotein (plasma fibronectin) levels after burn injury. Relationship to extent of burn and development of sepsis.

Authors:  M E Lanser; T M Saba; W A Scovill
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

10.  Mechanism of acute depletion of plasma fibronectin following thermal injury in rats. Appearance of a gelatinlike ligand in plasma.

Authors:  D C Deno; M H McCafferty; T M Saba; F A Blumenstock
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.